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Abstract
Aside from inheriting half of the genome of each of
our parents, we are born with a small number of
novel mutations that occurred during gametogenesis
and postzygotically. Recent genome and exome
sequencing studies of parent–offspring trios have
provided the first insights into the number and
distribution of these de novo mutations in health
and disease, pointing to risk factors that increase
their number in the offspring. De novo mutations
have been shown to be a major cause of severe
early-onset genetic disorders such as intellectual
disability, autism spectrum disorder, and other
developmental diseases. In fact, the occurrence of
novel mutations in each generation explains why
these reproductively lethal disorders continue to
occur in our population. Recent studies have also
shown that de novo mutations are predominantly
of paternal origin and that their number increases
with advanced paternal age. Here, we review the
recent literature on de novo mutations, covering
their detection, biological characterization, and
medical impact.
Introduction
Upon fertilization, a human zygote inherits half of its
genome from the mother via the oocyte and the other
half from the father through the sperm. In addition to
the genetic information passed on from generation to
generation, each of us is born with a small number of
novel genetic changes—de novo mutations—that occurred
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either during the formation of the gametes or postzygoti-
cally [1, 2]. Additionally, novel mutations continue arising
throughout post-natal and adult life in both somatic and
germ cells. Only mutations present in the germ cells can
be transmitted to the next generation [3].
There is a long-standing interest in the study of the
frequency and characteristics of de novo mutations in
humans, as these are crucial to the evolution of our
species and play an important role in disease. A typical
human genome varies at 4.1 to 5.0 million positions com-
pared with the human reference genome [4]. The vast
majority of genetic variation observed in a typical human
genome is common and shared by more than 0.5% of
the population as a result of having been recombined,
selected, and passed on for many generations [4]. By
contrast, a typical human genome contains 40,000 to
200,000 rare variants that are observed in less than 0.5%
of the population [4]. All of this genetic variation must
have occurred as a de novo germline mutation in an indi-
vidual at least once in human evolution [5]. Historically,
the germline mutation rate in humans has been calcu-
lated by analyzing the incidence of genetic disorders; in
1935, Haldane estimated the mutation rate per locus per
generation based on the prevalence of hemophilia in the
population [6, 7]. More recently, in 2002, Kondrashov
accurately calculated the de novo mutation rate in humans
by examining the mutation rate at known disease-causing
loci [8]. Nowadays, next-generation sequencing (NGS)
approaches in parent–offspring trios can be used to directly
study the occurrence of all types of de novo mutations
throughout the genome, from single-nucleotide variants
(SNVs) to small insertions–deletions (indels) and larger
structural variations (Box 1). Genome-wide NGS studies
place the germline de novo mutation rate for SNVs in
humans at 1.0 to 1.8 × 10–8 per nucleotide per generation
[1, 9–13], with substantial variation among families
[11, 13, 14]. This number translates into 44 to 82 de novo
single-nucleotide mutations in the genome of the average
individual, with one to two affecting the coding sequence
[9, 10, 12, 13, 15]. These state-of-the art genomic
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Box 1 Sequencing technology and de novo mutations
Box Fig. 1 Technical improvements to the detection of de novo mutations (DNMs). a Trio-based sequencing allows the identification of
de novo mutations in an individual. b Increased sequencing coverage benefits the detection of de novo mutations (in blue). Low cover-
age (upper) reduces the probability that a de novo mutation will be sequenced and called, compared with high sequencing coverage
(lower). c Using random tags or unique molecular identifiers (UMIs) decreases the number of false positives (in red) by making consensus
calls from all reads with the same UMI. Furthermore, UMIs can be used to remove PCR-derived duplicate reads to determine accurately
the allelic ratio. d Long sequencing reads improve mappability, even across difficult genomic regions such as those containing repeats
(gray boxes). Additionally, long reads can be used to phase mutations (shown in blue and in green) and generate haplotypes, to help
identify the parent of origin of a mutation. IV inherited variant.
Whole-exome sequencing (WES) and whole-genome sequencing (WGS) provide the possibility to perform an untargeted exome- or
genome-wide analysis of an individual’s DNA and, in theory, detect all the genetic variation present in an individual. By applying these
approaches in parent–offspring trios, one can determine which variants are inherited and which have occurred as de novo mutations in
the offspring. The trio design shown in Box Fig. 1a allows investigators to focus directly on the 44 to 82 de novo mutations arising in
the human genome per generation. Most current technologies rely on re-sequencing, which is short-read sequencing followed by
mapping and comparison to the human reference genome [199], relying on the raw sequencing quality [200] as well as the mapping
quality of the NGS reads [201].
The detection of de novo mutations requires high-quality and high-coverage sequencing (Box Fig. 1b) of three samples; de novo
mutations need to be detected in the offspring, and the corresponding base pair needs to be called as wild type in both parental
samples in a reliable manner. Poor quality and/or low sequencing coverage of any one of the three analyzed samples severely compro-
mises the reliable detection of de novo mutations. Postzygotic de novo mutations represent an additional challenge as mutations are only
present in a small percentage of cells and, upon sequencing, can resemble false-positive sequencing artifacts. For this type of mutation,
high sequence coverage is even more crucial. Independent validation by Sanger sequencing (only for validation of germline de novo
mutations owing to the low sensitivity of the method) and/or targeted NGS approaches remains essential in the case of uncertainty,
especially if a de novo mutation might be of diagnostic relevance. Improvements in raw sequencing quality and higher-coverage sequencing
will greatly improve the detection of de novo mutations and allow the consistent identification of postzygotic de novo mutations present in
small subsets of cells.
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approaches allow us to determine additional characteris-
tics of de novo mutations, such as the parental origin and
whether they occurred in the germline or postzygotically.
We now know that the majority of germline de novo mu-
tations have a paternal origin and that a higher paternal
age at conception results in an increase in the number of
de novo mutations in the offspring [15–18]. Furthermore,
the study of large cohorts of parent–offspring trios pro-
vides insight into the distribution of mutations throughout
the genome, the genomic context in which they arise, and
possible underlying mechanisms [11–13] (see Fig. 1 for an
overview of different mechanisms resulting in de novo
mutations).
Mutations conferring a phenotypic advantage propagate
rapidly through a population [19–21], whereas neutral
mutations can disseminate merely as a result of genetic
drift [22]. However, damaging mutations resulting in
deleterious traits before or during the reproductive phase
undergo purifying selection, and their spread through
the population is averted [23]. This entails that de novo
mutations are genetically distinct from inherited variants,
as they represent the result of the mutagenic processes
taking place between one generation and the next, before
undergoing selection (Table 1). Loss or acquisition of
traits at the population level drives evolution of a species,
whereas, at the level of an individual, loss or acquisition of
traits can result in disease.
Germline de novo genetic alterations have been impli-
cated in human disease for decades. Virtually all disease-
causing aneuploidies arise as de novo events. The best
known example for this is trisomy 21, identified in 1959
as the cause of Down syndrome [24]. In the beginning of
this millennium, genomic microarray technology provided
insight into the role of de novo copy-number variations
(CNVs) in disease [25]. Even though large CNVs occur
at a very low rate, arising at a frequency of only 0.01
to 0.02 events per generation [25–27], they contribute
significantly to severe and early-onset neurodevelopmental
disorders and congenital malformations owing to their
disruptive effect on many genes [28]. The magnitude of
the contribution of de novo genetic alterations to human
disease, however, has only recently become fully apparent
now that NGS approaches allow the reliable and affor-
dable detection of all types of de novo mutations [25].
Damaging de novo point mutations and indels affecting
important genes in development have been established as
a prominent cause of both rare and common genetic
disorders [29–35].
In this review, we first touch on the biological aspects
of de novo mutations in humans, such as their origin,
distribution throughout the genome, and factors related
to their occurrence and timing. Later, we discuss the
increasingly recognized role of de novo mutations in hu-
man disease and other translational aspects. Throughout,
we will focus mostly on de novo SNVs; readers should
refer to Box 2 and previous work from others for more
information on the role of de novo CNVs and other
structural genomic variation in human disease [36, 37].
Causes of de novo mutations
Mistakes during DNA replication can give rise to de novo
mutations as a result of the erroneous incorporation of
nucleotides by DNA polymerases [38]. DNA polymerases
ε and δ catalyze replication predominantly in the leading
and lagging strand, respectively. Both polymerases inte-
grate nucleotides during polymerization in a highly selec-
tive way, with an average of one mismatch per 104–105 bp
in vitro [39, 40]. A proofreading subunit present in both
(See box on previous page.)
A recent improvement for targeted re-sequencing is single-molecule tracing (Box Fig. 1c), which is based on the incorporation of random
tags or unique molecular identifiers (UMIs) to each DNA molecule during capture. UMIs can be used to remove duplicates from the
sequencing reads, but they can also allow consensus calling of PCR-derived duplicates of the same DNA molecule [202]. This is of particular
interest for the study of mosaicism, in which a mutation is present in only a fraction of all analyzed cells, such as postzygotic de novo
mutations [88].
In addition, the affordable and widespread use of long sequencing-read technology (Box Fig. 1d) [203] in the coming years is expected
to improve greatly the detection and characterization (including precise breakpoint mapping, length measurement, and exact copy-
number state) of small indels, repeat-expansions, as well as CNVs and more-complex structural genomic variation such as inversions and
chromosomal rearrangements by improving mappability and even allowing for de novo genome assembly [204–206]. For instance,
long-read sequencing technologies identify 85% of novel indels and CNVs with an average size close to 500 bp that were missed by
other methods [205]. The application of this technology in parent–offspring trios will provide a better insight into the frequency and role
of different types of de novo mutations in health and disease. The use of longer sequencing reads is also particularly useful to determine
the parental origin of a de novo mutation that requires mutation phasing (that is, deriving haplotypes) by making use of inherited SNVs on
the mutant allele. With currently available short-read sequencing technology, phasing can identify the parental origin for ~20% of de novo
mutations [13].
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Fig. 1 Mechanisms of de novo mutations. De novo mutations can arise because of static properties of the genome, such as the underlying sequence
(deamination of methylated CpGs, transitions versus transversions) or due to erroneous pairing of nucleotides during DNA replication. However, de
novo mutations can also occur in relation to cell-specific properties such as the chromatin state, transcriptional status, and gene expression levels.
Mutational hotspots for genomic rearrangements are largely determined by the underlying genomic architecture. One such example is given for
non-allelic homologous recombination (NAHR). Arrows represent the influence of each feature on the de novo mutation rate. Green arrows pointing
upwards indicate elevated mutability; red arrows pointing downwards indicate lower mutability. M methyl group modifying cytosine
Table 1 Comparison of inherited and de novo variants
Inherited variants De novo mutations
Single-nucleotide variants (SNVs) 3.5 to 4.4 million [4] 44 to 82 [9, 10, 12, 13, 15]
Number of coding SNVs 22,186 [10] 1–2 [25]
Insertions and deletions (indels <50 bp) ~550,000 [4] 2.9–9 [26, 91]
Large indels (50–5000 bp)a ~1000 [4] 0.16 [26]
Copy-number variations (CNVs) ~160 [4] 0.0154 [26]b
Selection pressure in previous generation(s) High None
Damaging capacity of variants Majority with small effect High
Differences in population Yes None
Parental/paternal age effect None Strong
Detection of variants Imputable Not imputable
Amenable to positional cloningc Yes No
aOwing to technical limitations, the number and mutation rate for large indels ranging between 50 and 5000 bp remain uncertain. Novel sequencing approaches
will likely provide more-accurate estimates (see Chaisson et al. [205])
bPer generation for CNVs larger than 100 kb
cPositional cloning by linkage analysis or homozygosity mapping
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polymerases subsequently verifies the geometry of the
paired nucleotides to ensure that the incorporated base
is correct [38].
Single or multiple base-pair mismatches can cause al-
terations in the structure of the replicating DNA and can
be restored by the mismatch repair (MMR) pathway [41].
The MMR pathway is highly efficient, which explains why
the amount of mutations generated during DNA replica-
tion is much lower than the polymerase error rate. The
frequency at which specific base-pair substitutions arise
can be different from the speed at which they are repaired,
which defines the mutation rates for specific base-pair
substitutions [41]. Incomplete repair can lead to single or
multiple base-pair substitutions or indels. Additionally,
damaged nucleotides can be incorporated during replica-
tion, leading to mispairings and base substitutions [42].
DNA lesions can also appear spontaneously as a con-
sequence of exogenous or endogenous mutagens—UV
or ionizing radiation and DNA-reactive chemicals are an
example of the former, whereas reactive oxygen species
belong to the latter [38]. Before replication, these spon-
taneous lesions are repaired mainly by the nucleotide
excision repair system and base excision repair pathways
[43]. However, inefficient repair of pre-mutations before a
new round of DNA replication can lead to the mutation
becoming permanently fixed in either one or both
daughter cells [44]. If mutation repair fails, DNA replica-
tion might also be completely arrested and ultimately lead
to cell death [44].
The difference between the rate at which pre-mutagenic
damage appears in DNA and the rate at which it is
repaired defines the rate at which de novo mutations arise.
It is often assumed that germline de novo mutations
originate from errors in DNA replication during gameto-
genesis, particularly in sperm cells and their precursors
(see section below on parental origin of de novo muta-
tions). However, inefficient repair of spontaneous DNA
lesions can also give rise to de novo mutations during
spermatogenesis, as continuous proliferation and short
periods between cell divisions can translate into there
being less time to repair these lesions [44, 45]. Furthermore,
in oogenesis, spontaneous DNA mutations coupled to inef-
ficient repair mechanisms might play a more prominent
role [44]. Therefore, while the de novo mutation rate is a
reflection of the replication error rate and the number of
mitoses a cell has undergone, this number is also influenced
by the amount of time between mitoses and the efficiency
of the DNA repair [44].
Distribution of de novo mutations in the genome
While the typical human mutation rate is 1–1.8 × 10–8 per
nucleotide per generation [1, 9–13], mutagenesis does
Box 2 De novo copy number variations and other structural variations
Copy-number variations (CNVs) are defined as deletions or duplications affecting 1000 nucleotides or more [207]. Because of their size,
CNVs often have a negative effect on fitness and therefore undergo purifying selection. As a result, there are relatively few inherited CNVs
per genome (approximately 160) [4], and de novo germline CNVs are a well-known cause of severe congenital malformations
and neurodevelopmental disorders [208–210].
Genomic microarrays have been instrumental for the initial detection and characterization of CNVs with a size below light-microscope
resolution [25]. However, NGS has recently shown superior resolution for the detection of CNVs using both short and long sequencing-
read approaches and data analysis focusing on depth of sequence reads, split reads, and paired-end reads [211, 212]. The rate at which large
de novo CNVs (over 100,000 bp) arise in the human genome is estimated to lie between 0.01 and 0.02 events per generation [25–27]. The
mutation rate for indels and CNVs, ranging in size between 10 and 10,000 bp, remains uncertain owing to technical limitations in the
detection of these events with short-read sequencing technology.
The CNV mutation rate varies several orders of magnitude depending on the genomic region and parent-of-origin as a result of
differences in the mechanism by which the de novo CNV arises [213]. Similar to what has been observed for SNVs, non-recurrent
de novo CNVs also show a strong paternal bias and age effect [15, 214]. This correlation highlights a possible mitotic origin for
these mutations, resulting from fork stalling and template switching during DNA replication [215]. By contrast, the occurrence of recurrent
de novo CNVs, many of which cause well-known developmental syndromes [216], is strongly dependent on the underlying genomic architec-
ture [36]. For instance, the distribution and orientation of segmental duplications (also termed “low-copy repeats”) is known to create “hot spots
for structural variation” mediating recurrent CNVs by non-allelic homologous recombination during meiosis (NAHR; Fig. 1) [36, 216]. A strong
maternal bias for these types of CNVs has been observed at specific loci [217], which might be explained by a higher local
maternal recombination rate. Additionally, for a number of recurrent de novo CNVs, it has been shown that the parental allele
carries an inversion that places the duplicated flanking regions in tandem. Some of these inversions have reached high frequencies in specific
populations; for instance, the inversion leading to the so-called H2 haplotype on 17q21 is present in 20% of Europeans [218] and predisposes
to the occurrence of 17q21 microdeletion syndrome [219].
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not occur completely at random across the genome [9].
Variation in mutability across different areas of the gen-
ome can be explained by intrinsic characteristics of the
genomic region itself, related to its sequence composition
and functional context [46]. Certain factors playing a role
in the mutability of the genomic region are predicted to
be shared by all cell types in the human organism. These
include the local base-pair context, recombination rate,
and replication timing [9, 13, 47]. Replication timing
refers to the order in which different areas of the genome
are replicated during the S-phase of the cell cycle. Gen-
omic regions that are replicated late display more genetic
variation than regions that are replicated early [47]. It
has been suggested that this could be due to a higher
mutability that is secondary to depletion of dNTPs at
the end of replication, although other changes such as
alterations in polymerase activity and decreased MMR
repair activity have also been implicated [38, 48, 49].
Other factors influencing mutability can vary from cell
to cell, depending on the transcriptional activity and chro-
matin state [50–52]. In addition, recent whole-genome
sequencing (WGS) studies have revealed the presence of
so-called “mutational clusters” and “mutational hotspots”.
Mutational clusters correspond to the observation of mul-
tiple de novo mutations in very close vicinity in a single
individual, whereas multiple de novo mutations occurring
at the same location in several individuals are an indica-
tion of the existence of mutational hotspots [53].
Nucleotide differences: transitions, transversions, and
CpGs
The molecular events underlying transitions occur more
frequently than those leading to transversions, resulting
in a two-fold greater rate of transitions over transversions
across the genome [27, 38]. Transitions arise predomi-
nantly as a result of C > T mutations, which is at least
partially explained by the mutability of CpG dinucleotides
[54]. The cytosine in a CpG dinucleotide often undergoes
methylation at the fifth position of the six-atom ring, lead-
ing to 5-methylcytosine (5-mC). In humans, methylated
CpG dinucleotides are known to be chemically unstable
and highly mutable due to deamination of 5-mC at CpG
dinucleotides, resulting in G:T mismatches [12]. Indeed,
the mutability of CpG dinucleotides is approximately ten
to eighteen times higher than that of other dinucleotides
[27], and, as a result, CpG dinucleotides are found at
only a fraction of their expected frequency in the human
genome [54]. The high de novo mutation rate at CpG sites
is also illustrated by the recent work of the Exome Aggre-
gation Consortium (ExAC). Through the work of this
consortium, exome data from more than 60,000 individ-
uals without severe pediatric disease are currently avail-
able (Box 3). Analysis of the data in ExAC shows that the
discovery of new mutations at CpG dinucleotides reaches
saturation at 20,000 exomes [55, 56]. This emphasizes
that identical CpG mutations do not necessarily reflect an
ancestral event but are likely the result of independent de
novo mutations.
Remarkably, the mutability of CpG dinucleotides is
lower in genomic regions enriched for CpG and with
higher GC content than in the rest of the genome [44].
In fact, the mutation rate for CpGs in the GC-richest
regions of the genome are two to threefold lower
than in the rest of the genome [44, 48]. This could
be the result of lower methylation levels, the effect of
selection because the regions play a role in gene
regulation, or secondary to stronger binding between
DNA strands impeding separation and spontaneous
deamination [38, 44, 57].
Mutational signatures underlying specific mutational
processes
While errors in DNA replication, exposure to mutagens,
or failure to repair DNA damage can all result in muta-
tions, there are differences in the pattern of mutations
arising from each of these processes. A “mutational sig-
nature” has been defined as a pattern of mutations that is
specific to a mutational process occurring in a cell, tissue,
or organism [58]. A recent study based on the analysis of
4.9 million somatic mutations in more than 12,000 can-
cer genomes defined 21 mutational signatures associated
with mutational processes active in somatic cells (termed
signature 1 to 21) [58]. Detailed descriptions of each
signature are available at http://cancer.sanger.ac.uk/cos
mic/signatures. Each of these millions of mutations is
placed into one of 96 possible mutation types based on
six possible base pair substitutions (C > A, C > G, C > T,
T > A, T > C, and T >G) and one of four possible base
pairs adjacent to the mutation both at the 5′ and at the
3′ position of the mutation. Concisely, each mutation
type is a trinucleotide in which the middle base pair is
mutated to a specific nucleotide and each mutational
signature is defined by the frequency of each mutation
type observed [59].
A recent study showed that the mutational spectrum
of germline de novo mutations correlated best with
two of these previously described mutational signa-
tures, currently known as signatures 1 and 5 [11, 13].
This suggests that the mutational processes associated
with these signatures in somatic cells might also be
active in germ cells, although the mechanisms under-
lying the processes remain elusive. Mutational signa-
ture 1 represents close to 25% of de novo germline
mutations and is characterized by a high proportion of C >
T transitions at CpG dinucleotides, which is associated with
deamination of methylated cytosine [11, 58]. Muta-
tional signature 5, which corresponds to the remaining
75% of de novo mutations, is characterized mainly by
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A >G transitions [11]. While the mechanism under-
lying this signature remains unclear, the mutations ob-
served as part of this signature might be secondary to
spontaneous deamination of adenine to hypoxanthine,
which is then read as guanine [60]. This mutational signa-
ture is associated with transcriptional strand bias, sug-
gesting that some of these mutations arise from
adducts subject to transcription-coupled repair [60].
Mutational clusters and hotspots
De novo mutations occur throughout the human genome,
but occasionally several mutations can arise at a closer
distance than expected by random distribution [9]. The
term “mutational clusters” refers to the occurrence of de
novo mutations in an individual at a closer distance than
expected, with multiple de novo mutations within regions
ranging from 10 to 100 kb [9, 12, 13, 53]. Mutational
Box 3 Establishing causality for a de novo mutation
Although identifying de novo mutations is becoming increasingly easy, interpreting them (i.e., linking them to a phenotype) often
remains challenging [220]. Clinical interpretation of de novo mutations requires evaluation at the level of the affected locus or gene, as well
as at the variant level [221].
For the interpretation of candidate disease-causing de novo mutations, it is important to verify that the phenotype of the patient
with the identified mutation matches that of patients described in the literature possessing similar mutations. Next, the de novo
mutation can be evaluated by the same methods used to interpret inherited variations, such as in silico prediction programs such as SIFT,
PolyPhen, MutationTaster, and CADD [221–224]. Traditionally, evidence linking a gene or a mutation to a phenotype has been established
experimentally [221, 223], although functional validation is laborious and the necessary assays can differ per gene and per mutation. Many
recent developments can support the interpretation of de novo mutations in human disease. For instance, to study the consequences of a
mutation, induced pluripotent stem cells from patient-derived samples can be differentiated into cell types relevant for the respective disease
[225]. Furthermore, as a robust method for in vitro and in vivo genetic manipulation, the “clustered regularly interspaced short palindromic
repeats” CRISPR–Cas9 system can be used to establish cell and animal models for functional studies [226, 227]. Other CRISPR/Cas9-based
methods, such as “saturation genome editing”, hold promise for the evaluation of hundreds of mutations in a single assay [228], allowing the
interpretation of de novo mutations to keep pace with their discovery in the genomics era.
Replication is essential to establish the link between de novo mutations in a novel disease gene and a phenotype [189]. This initially
involves the identification of de novo mutations in the same gene in two or more individuals sharing a similar phenotype. However,
large-scale parent–offspring sequencing studies have made apparent that this, by itself, is not sufficient to establish causality for a disease
[221]. The number of de novo events identified in a specific gene in individuals with the same phenotype must exceed the expected
background rate of de novo mutations, which depends on specific features of each gene, such as its size, sequence, and constraint [126].
This approach has been used successfully to identify new disease genes for autism spectrum disorders [229], epileptic encephalopathies [31],
and intellectual disability [128]. A novel way to find more patients with de novo mutations in the same gene is emerging from genetic
matchmaking platforms such as Matchmaker exchange (http://www.matchmakerexchange.org/) [230] or GeneMatcher (https://www.gene-
matcher.org/) [231], which enable easy data sharing. Establishing unequivocally a link between a genotype and a phenotype requires the same
meticulousness in patient phenotyping as in their genotyping, and objective criteria are needed to be able to compare clinical features in
patients. For large heterogeneous patient cohorts, systematic phenotyping, including an assessment in Human Phenotype Ontology (HPO)
terms, can prove beneficial and increase the diagnostic yield in exome sequencing [127, 232–234].
Large-scale databases of genetic variation can be used to see whether a gene or gene region shows constraint against variation in
controls, as the frequency of a mutation in the population is often a good indirect estimation of its pathogenicity [223]. To this end, RVIS
and selective constraint scores have become routine in the interpretation of de novo variants, both in research and in the clinic [126, 188].
Population databases, such as the Exome Aggregation Consortium (ExAC) [55], are expected to be depleted of de novo disease-causing
mutations for severe and early-onset disorders. Given that de novo mutations are the rarest type of variation, the absence of a mutation from
the ExAC database is not in itself sufficient evidence for its pathogenicity. By contrast, the presence of a mutation in ExAC does not
automatically entail that the mutation is not disease causing. Pathogenic mutations involved in dominant disease are present in ExAC [55],
which might be explained by variable penetrance for these variants [235], the presence of false-positive variants in the control database [236],
or undiagnosed disease in control individuals. Possible other explanations for these observations could be the presence of these mutations
as somatic events in control individuals [106–108] or resilience to disease in a few selected individuals [237].
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clusters display a unique mutational spectrum, with a
lower rate of transitions and a large proportion of C > G
transversions [13]. This phenomenon has been described
to arise in somatic cells in the context of cancer,
where it is known as “kataegis”, and is linked to the fam-
ily of enzymes known as APOBEC (for “apolipoprotein B
mRNA editing enzyme, catalytic polypeptide-like”) [53,
58]. It has been suggested that clusters involving C > G
transversions could be related to the formation of single-
stranded DNA in diverse cellular processes, such as
double-strand breaks and dysfunctional replication forks
[61]. Single-stranded DNA might be mistaken for retroe-
lements and attacked by APOBEC enzymes, which con-
vert cytosine to uracil [53]. The mutations are then
repaired through base-excision repair and subsequent
translesional DNA synthesis with error-prone polymer-
ases [38]. Indeed, mutational clusters have been
described to be reminiscent of APOBEC-mediated muta-
tions, albeit with a different sequence context [12, 13].
The occurrence of mutational clusters has been found to
correlate with increased parental age [13].
Another origin for some of these clusters could be
chromosomal rearrangements. It has been shown that
the mutation rate for SNVs is elevated and SNVs can
cluster in proximity to the breakpoints of de novo CNVs
[62, 63]. This is likely the result of the replicative CNV
mechanism in which a low-fidelity, error-prone DNA
polymerase is used during repair of DNA. Indeed, work
performed in yeast supports the observation that double-
strand-break-induced replication is a source of mutation
clusters [61].
In contrast to the mutation clusters that occur within
one individual, mutational hotspots are considered over-
lapping loci that are found to be mutated more frequently
than expected in different individuals. Recent research
based on WGS datasets and modeling has identified such
hotspots in coding sequences [9]. Furthermore, the exist-
ence of these mutational hotspots has been recently
confirmed in a larger study that showed specific bins of
1 Mb within the human genome with elevated mutation
rates [13]. Interestingly, in this study, two bins including
genes CSMD1 and WWOX were shown to have a higher
maternal than paternal mutation rate. The mechanism
for this is still largely unknown, but the latter is a
well-known fragile site within the human genome [64].
Other sites of the human genome that are especially prone
to de novo mutations include ribosomal DNA (rDNA)
gene clusters [65], segmental duplications [66], and micro-
satellites [67], with mutation rates three to four orders of
magnitude higher than average [68].
Parental origin of de novo germline mutations
In human embryos, the primordial germ cells (PGCs)
emerge from the epiblast, eight to fourteen cell divisions
after fertilization [69]. In these first cell divisions, the
mutation rate appears to be similar in male and female
embryos (approximately 0.2–0.6 mutations per haploid
genome per cell division, according to models estimating
the mutation rate during gametogenesis) [11]. After their
specification, PGCs expand to form the pool of sperm-
atogonial stem cells and the complete population of pri-
mary oocytes in male and female embryos, respectively
[11, 69]. Despite differences in the expansion of PGCs to
oogonia or spermatogonia, the mutation rate during this
step is similar in both sexes, with approximately 0.5
to 0.7 mutations per haploid genome per cell division,
according to computational modeling [11]. However, after
puberty, the processes involved in spermatogenesis and
oogenesis diverge further. Spermatogonial stem cells div-
ide by mitosis approximately every 16 days, maintaining
the spermatogonial stem cell pool while generating diffe-
rentiated spermatogonial cells which produce sperm cells
through an additional round of mitosis followed by mei-
osis [70]. By contrast, each menstrual cycle, a few oocytes
escape from meiotic arrest and complete the first meiotic
division. After ovulation, the oocyte becomes arrested
once more until fertilization, when it completes the sec-
ond meiotic division. Thus, after PGC expansion in em-
bryogenesis, oocytes only undergo one additional round
of DNA replication in their evolution to a mature ovum.
In contrast, spermatogonial cells can undergo hundreds
of rounds of DNA replication and cell division before
their maturation to sperm cells.
Approximately 80% of all de novo germline point muta-
tions arise on the paternal allele, and advanced paternal
age at conception has been established as the major factor
linked to the increase in the number of de novo mutations
in the offspring, both at the population level and within
the same family (Fig. 2) [11, 13, 15]. Spermatogonial cells
continue to divide throughout life, which is likely to allow
the progressive accumulation of mutations due to errors
during DNA replication but also as a result of failure to
repair non-replicative DNA damage between cell divisions
[44]. Furthermore, the efficiency of endogenous defense
systems against radical oxygen species and of DNA repair
mechanisms might also decline with age [71, 72]. De novo
mutations in children of young fathers show a different
signature and localize to later-replicating regions of the
genome compared with those of children of old fathers,
suggesting that additional factors contribute to de novo
mutations with age [12, 13]. It has been calculated that
one to three de novo mutations are added to the germline
mutational load of the offspring for each paternal year at
conception, but this effect varies considerably between
families [11, 13]. This variability has been suggested to be
due to individual differences in the rate of mutagenesis, in
the frequency of spermatogonial stem cell division and
even to genetic variation in DNA mismatch repair genes
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[11]. Indeed, one could speculate that deleterious variation
in genes involved in replication and repair could predis-
pose to elevated de novo mutation rates not only in som-
atic cells but also in the germline, as has been observed
in mouse models lacking exonuclease activity in DNA
polymerase δ [73].
The effect of increased maternal age is well established
for errors leading to chromosomal nondisjunction involved
in aneuploidies [74, 75], but less so for de novo point mu-
tations. The fixed number of mitoses required for ooge-
nesis would entail that maternal age would not be linked
to an increase in DNA-replication-associated mutations.
However, an effect of maternal age on the number of de
novo mutations has been reported recently [13, 76], likely
reflecting an excess of non-replicative DNA damage that is
not properly repaired [44]. This maternal age effect was
initially reported in a study analyzing de novo mutations in
WGS data from a large cohort of parent–offspring trios, in
which maternal age correlated with the total number of de
novo mutations after correcting for paternal age [76]. A
more detailed analysis of the same cohort confirmed a sub-
tle but significant increase in the number of maternal de
novo mutations with advancing maternal age, comprising
0.24 additional de novo mutations per extra year of mater-
nal age at conception [13]. Previous studies had failed to
identify a maternal age effect on the number of de novo
mutations [12, 15]. This might be explained by differences
in the parental age distribution between cohorts or due to
a lack of statistical power to detect this subtle effect for
which paternal age is a confounder [76]. The increase of de
novo mutations with advanced paternal and maternal age
support the possibility that the accuracy of DNA repair
mechanisms in germ cells decreases with age [72].
Selective advantage of de novo mutations in the testes
A striking increase with paternal age has been observed
for a small subset of de novo mutations that are highly
recurrent and localize to specific nucleotides in the gen-
ome. These de novo mutations are thought to grant sperm-
atogonial stem cells a growth advantage, leading to clonal
22 mitoses
Parental
postzygotic
~4%1
Postzygotic
~7%3
Germline
89%2
23 mitoses/year
100-150 mitoses in
a 20 year old man
de novo mutations
44-82 SNVs4
(1-2 coding)
3-9 indels
0.015 CNVs
Young parents
22 mitoses23 mitoses/year
~610 mitoses in
a 40 year old man
1-3 DNMs per additional year in paternal age at conception
0.24 DNMs per additional year in maternal age at conception
increase in indels and CNVs
Old parents
Fig. 2 Timing of de novo mutations (DNMs). Sperm cells have undergone approximately 100 to 150 mitoses in a 20-year-old man, whereas
oocytes have gone through 22 mitoses in a woman of the same age (left). As a result of errors in both replication of the genome and repair of DNA
damage occurring during parental embryogenesis, gametogenesis, or as postzygotic events in the offspring, DNMs arise in each new generation.
Advanced parental age is associated with an increase in the number of de novo mutations (right). The male germline adds 23 mitoses per year,
entailing that a spermatogonial stem cell in a 40-year-old man has undergone more than 600 cell mitoses. Each additional year in paternal age
at conception adds one to three de novo mutations to the genome of the offspring. Oogenesis has a fixed number of mitoses, but mutations
accumulate over time possibly owing to failure to repair DNA damage. The increase in number of de novo mutations with maternal age is lower:
0.24 extra de novo mutations for each additional year of maternal age at conception. Cell lineages modified from [238]. Somatic cells are showed
in orange, the male germline is shown in blue, and the female germline is shown in purple. Blue stars represent postzygotic mutations present in
the germline and in somatic cells; yellow stars represent mutations arising exclusively in the germline; red stars represent somatic mutations arising
during embryonic development or post-natal life which are absent from germline cells. Figure footnotes: 1The ratio of paternal to maternal
mutations originating from parental gonosomal mosaicism is 1:1; 2the ratio of paternal to maternal germline de novo mutations is 4:1; 3the
ratio of paternal to maternal postzygotic de novo mutations is 1:1; 4this range is based on the average number of de novo mutations
published elsewhere [9, 10, 12, 13, 15] irrespective of parental age
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expansion of mutated cells in the testis [77]. For instance,
gain-of-function mutations in genes in the RAS–MAPK
pathway have been shown to cause clonal expansion of mu-
tant spermatogonial stem cells owing to proliferative selec-
tive advantage [77, 78]. Computational modeling suggests
that this would result from a slightly increased ratio of
symmetric versus asymmetric divisions in mutant sper-
matogonial stem cells, favoring the production of two
mutated spermatogonial stem cells compared with a single
mutated stem cell and one differentiated spermatogonial
stem cell harboring the mutation [79, 80]. Therefore, over
time, spermatogonial stem cells carrying these mutations
undergo positive selection owing to higher self-renewal
than surrounding wild-type cells and expand clonally in
the testis [81]. The occurrence and enrichment of muta-
tions in spermatogonial stem cells is thought to take place
in all men and would entail that the testes of older men
contain a higher number of clones of mutant spermato-
gonial stem cells [77, 78].
Interestingly, the first mutations implicated in clonal
expansion in spermatogonial stem cells were initially
shown to cause developmental disorders such as Noonan
and Costello syndrome (caused by PTPN11 and HRAS
mutations, respectively) [78, 81, 82], Apert, Crouzon,
and Pfeiffer syndromes (FGFR2) [81, 83], achondroplasia,
Muenke syndrome and thanatophoric dysplasia (FGFR3)
[81, 82], and multiple endocrine neoplasia (RET) [84].
Mutations that are positively selected at the spermatogo-
nial stem cell level but are detrimental at the organism
level have been termed to behave selfishly and are there-
fore referred to as “selfish mutations” [82]. Owing to the
expansion of mutant cells over time, the incidence of these
developmental disorders shows an exponential increase
with paternal age at conception, well beyond the increase
observed for other disorders caused by de novo mutations
[85]. Appropriately, these disorders are known as “recur-
rent, autosomal dominant, male-biased, and paternal”
(RAMP) age effect disorders or, simply, paternal age effect
(PAE) disorders [45, 78]. Because of the selfish selection
of mutant spermatogonial cells, PAE disorders have an
incidence up to 1000-fold higher than expected based on
the mutational target size and the average mutation rate
[45, 85]. It has been hypothesized that “selfish mutations”
with a weaker effect on spermatogonial stem cell behav-
ior could be involved in more-common phenotypes, such
as intellectual disability, autism, or epilepsy [86]. Further-
more, “selfish” behavior is a characteristic of certain
mutations driving cancer as they lead to positive cellular
selection despite being harmful for the organism. Predict-
ably, several mutations behaving selfishly in spermatogo-
nial stem cells have also been identified as somatic events
driving clonal growth in tumorigenesis [82].
Following the identification of genomic regions enriched
for maternal de novo mutations [13], the possibility of
selfish mutations in the maternal germ line has also been
put forward [72]. It appears that these genomic regions
harbor genes with a role in tumor suppression, and some
de novo mutations could, it is speculated, provide mutant
oocytes in aging women with a survival advantage over
wild-type ones [72].
Timing of de novo mutations
De novo mutations have traditionally been considered to
occur as germline events, but the advent of NGS allowed
scientists to demonstrate that de novo mutations occur
as non-germline events more often than previously esti-
mated [3, 87–89]. Mosaicism, which is the existence of
two or more genetically distinct cell populations in an
individual developing from a single fertilized egg [90], is
the norm rather than the exception. Postzygotic muta-
tions, that is, mutations arising in the first few cell divi-
sions after fertilization, can lead to high-level mosaicism
and be present in many different tissues of an organism.
Mutations that arise later in development or post-natal
life, by contrast, can remain restricted to a single tissue or
even to a small number of somatic cells (Fig. 2).
Approximately 7% of seemingly de novo mutations are
present in blood as high-level mosaic mutations, having
likely occurred as early postzygotic events [88, 89, 91].
This, together with the observation that chromosomal
instability and structural rearrangements are common in
cleavage-stage human embryos, has led to the suggestion
that early embryogenesis might be a period of high mut-
ability [92, 93]. Before the initiation of transcription and
translation in the zygote, human embryos rely on maternal
proteins contributed by the oocyte [94], which could lead
to a shortage of proteins involved in DNA replication and
repair, resulting in genomic instability [3]. Depending on
the timing at which a de novo mutation arises during em-
bryonic development, it could be present at different levels
in multiple tissues or be organ specific [95]. A recent
study examined multiple samples from the same indivi-
dual and showed the widespread presence of postzygotic
de novo mutations in tissues of different embryonic origin,
including somatic and germ cells [96]. Furthermore, mu-
tations can arise in the germ cell lineage after the speci-
fication of PGCs during early embryonic development,
remaining isolated from somatic cells [3]. Although these
mutations are undetectable in sampled tissues such as
blood or buccal swabs, they can be transmitted to the
offspring as germline events.
Somatic cells are predicted to accumulate hundreds
of different mutations throughout post-natal and adult
life [97]. Large chromosomal abnormalities have been
observed in many tissues in the human body [98], such as
the blood, where the presence of these lesions in-
creases with age [99–101]. For instance, loss of the Y
chromosome in blood cells has been described as a
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frequent event in aging males, affecting over 15% of men
aged 70 years or older [102, 103]. Somatic mutations
resulting in low-level mosaicism are prevalent in healthy
tissues [104], including the brain [105], blood [106–108],
and skin, where the somatic mutation rate has been calcu-
lated at two to six SNVs per megabase of coding sequence
per cell [109]. As a result of the accumulation of somatic
mutations, the genome sequence is certain to vary among
different cells of an individual, a level of genetic diver-
sity that is best observed with single-cell sequencing
technologies [110]. Studies in mouse models have shown
that the mutation frequency is higher in somatic cells than
in germ cells [111, 112]. The comparison of the somatic
and germline mutation rate in humans supports this find-
ing, which might stem from differences in the efficiency of
DNA replication and repair mechanisms in germ and
somatic cells, in addition to differences in exposure to
mutagens [72].
De novo mutations in human disease
The medical relevance of de novo mutations has only
recently been fully appreciated, mainly because advances
in sequencing technology have allowed a comprehensive
analysis of these mutations [25]. The field of human gene-
tics had previously focused primarily on inherited diseases,
leaving sporadic disorders largely untouched. This was
because traditional disease gene identification methods
relied mainly on positional mapping of disease loci in large
pedigrees with multiple affected members, followed by
Sanger sequencing to identify disease-causing mutations
in candidate genes. By contrast, NGS techniques such as
whole-exome sequencing (WES) or WGS now provide
the possibility to detect most, if not all, genetic variation
present in a patient. To this end, trio-based WES or WGS
has been instrumental in detecting and characterizing de
novo mutations in patients with a wide variety of diseases
(Box 1) [25, 35].
De novo mutations in pediatric disease
De novo mutations are now well known to play an im-
portant role in severe early-onset diseases, which for the
most part arise sporadically because of their impact on
fitness; owing to the severity of the phenotype in which
they often result, an individual with a deleterious de
novo mutation will not produce offspring and the
phenotype therefore only arises through de novo
mutations.
In the first 5 years of widespread availability of WES,
more than 500 novel disease–gene associations have
been identified, with the strongest increase in sporadic
diseases caused by de novo mutations [35, 113, 114]. Re-
cent studies applying exome sequencing in the clinic
have shown that of all sporadic cases that received a mo-
lecular diagnosis through clinical exome sequencing,
between 60 and 75% could be explained by de novo mu-
tations [115, 116]. De novo mutations affecting the cod-
ing region have also been established as an important
cause of common neurodevelopmental disorders, such
as autism [29, 30], epilepsy [31], and intellectual disabil-
ity [33, 34], which affect over 1% of the population [117,
118]. Clearly, these common genetic disorders are not
explained by de novo mutations affecting the same locus
in every patient. Instead, an extreme genetic heterogen-
eity is observed, and patients with common genetic disor-
ders carry de novo mutations in many different genes.
The population frequency of a disorder caused by de novo
mutations is determined in large part by the number of
genes or genetic loci that can result in this disorder
when mutated, which we have referred to previously as
the “mutational target” [25]. Rare disorders are most often
caused by mutations in a single gene or a small number of
genes, while common genetic disorders usually have a
large mutational target, often comprising hundreds to
thousands of genes or genetic loci. [25]. As an example,
more than 700 genes have now been identified to cause
autosomal dominant intellectual disability when mutated
[117], and this number is rapidly increasing since the
widespread application of NGS technology. Based on
these sequencing studies, it appears that the majority of
the most severe neurodevelopmental phenotypes, such as
severe intellectual disability with an IQ below 50, are the
consequence of damaging de novo germline mutations in
the coding region [10]. An enrichment for damaging de
novo mutations has also been observed in individuals
with milder phenotypes such as autism spectrum dis-
order without cognitive deficits [16, 18, 29, 30, 119].
For these milder phenotypes that have less impact on
fitness, the exact contribution of de novo mutations to
the disease burden is not yet firmly established, and inher-
ited variation is likely to be at least as important in the ex-
pression of the phenotype [120–122]. Next to
neurodevelopmental disorders, de novo mutations also
play a prominent role in pediatric diseases such as congeni-
tal heart defects (CHDs) [123–125]. In agreement with the
observation made in neurodevelopmental disorders, recent
studies found the highest contribution of de novo muta-
tions to disease in individuals with the most severe
and syndromic forms of CHD [123, 125]. Finally, it is
essential in large-scale sequencing studies to test formally
whether the recurrence of de novo mutations in a gene
exceeds the number of observations expected by
chance (Box 3) [126].
The vast majority of pathogenic de novo mutations are
involved in dominant genetic disorders. This appears
logical, as a single damaging de novo mutation can be
sufficient to cause these kinds of disorders. However,
there are examples of recessive disorders that can be
caused by the combination of an inherited mutation on
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one allele and the occurrence of a de novo mutation on
the other [33]. In a cohort of 100 trios with severe ID,
we identified one case of autosomal recessive ID that
was due to the inheritance of one pathogenic allele
and the occurrence of a de novo hit in the other [33],
and similar observations in the context of late-onset
disease are described below. Furthermore, there are re-
ports of cases with a merged phenotype comprising
two clinically distinct disorders of which either one or
both are caused by a pathogenic de novo mutation
[115]. Phenotype-based and classic genetic approaches
are insufficient to diagnose individuals with this kind
of combined disease, illustrating the power of an unbiased
genotype-first approach. Additionally, this approach re-
duces the need for clinical homogeneity for disease–gene
identification studies, as was required for phenotype-first
approaches [127, 128].
De novo mutations in late-onset disorders
Few studies until now have addressed the role of de
novo mutations in late-onset diseases. The role of de
novo mutations is likely to be smaller in late-onset
disorders than in pediatric disorders given the effect
of de novo mutations on reproductive fitness. Never-
theless, genes involved in adult-onset disorders are
just as likely to be affected by de novo mutations as
genes involved in pediatric disorders. A complicating
factor in these late-onset disorders, however, is the
collection of parental samples for the study of de
novo mutations [129]. Despite this obstacle, recent
publications have suggested a link between de novo
mutations and late-onset neurological and psychiatric
disorders: Parkinson’s disease, amyotrophic lateral
sclerosis, schizophrenia, and bipolar disorder have
been associated with de novo SNVs and CNVs [130–
137]. For example, one study found that 10% of indi-
viduals with sporadic schizophrenia have a rare de
novo CNV compared with 1.26% for controls [132].
Exome sequencing of a cohort of 623 schizophrenia
trios identified an enrichment for de novo point mu-
tations in genes encoding synaptic proteins in cases
compared with controls [130]. A large meta-analysis
recently identified both an excess of loss-of-function
mutations in the histone methyltransferase SETD1A
and an excess of de novo occurrence of these muta-
tions in individuals with schizophrenia compared with
controls [138]. Recent studies have exposed a genetic
overlap between neurodevelopmental disorders and
schizophrenia, with de novo mutations in the same
gene being involved in both early and late-onset dis-
orders [138–140]. While de novo mutations have
been firmly linked to neurodevelopmental disorders,
their involvement in late-onset psychiatric phenotypes
is more controversial. This could be the result of a
more complex underlying genetic architecture [141], to-
gether with a more prominent role for environmental fac-
tors in the expression of the phenotype [142].
Cancer, particularly in relatively young individuals
without relevant family history, has been associated with
de novo mutations in genes involved in cancer-
predisposition syndromes. For example, at least 7% of
germline mutations in TP53 (encoding cellular tumor
antigen p53) in individuals with Li-Fraumeni syn-
drome occurred de novo [143], and a similar proportion
has been identified for mutations in APC involved in fa-
milial adenomatous polyposis [144]. Nevertheless, the rate
of de novo mutations in genes involved in other cancer-
predisposition syndromes, such as BRCA1 and BRCA2
[145], or in DNA mismatch repair genes (MLH1, MSH2,
MSH6, and PMS2) [146] has been reported to be much
lower.
Interestingly, de novo mutations have also been identi-
fied as causative mutations in genetic disorders that are
typically inherited, such as hereditary blindness. For in-
stance, the rate of causative de novo mutations among
sporadic cases within a cohort of patients with retinitis
pigmentosa was close to 10% [147], a result that was
later confirmed by an independent study [148]. Although
for the majority of this group the de novo mutation
represented a single dominant hit causative of the pheno-
type, in one case the de novo mutation was in fact the
second hit in an autosomal recessive form of retinitis
pigmentosa. Similarly, in a cohort suffering from mild-to-
moderate sensorineural hearing loss, de novo mutations
were identified in two out of eleven sporadic cases [149],
also suggesting a role for de novo mutations in this
heterogeneous disorder.
As de novo mutations are known to play an import-
ant role in disorders that affect fitness, it might also
be very relevant to investigate their role in disorders
linked to fertility, such as male infertility. Both de
novo chromosome Y deletions as well as de novo
point mutations in a few genes have been found to
cause this disorder [150, 151], but a systematic screen
is lacking so far.
Postzygotic de novo mutations in disease
The timing of a pathogenic de novo mutation can have an
important influence on the expression of the phenotype.
Postzygotic mutations are currently receiving more and
more attention as technological improvements allow the
detection of (low level) mosaic mutations for the first time
at a genome-wide scale (Box 1). Postzygotic de novo mu-
tations have been identified as the cause of several human
diseases, ranging from developmental disorders [152–154]
to cancer [155–157]. While de novo mutations arising
later in development and leading to gonadal or gonosomal
mosaicism might be clinically silent in that individual,
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there is an increased likelihood that the mutation is trans-
mitted to the offspring as a germline event, resulting in a
clinical disorder [158].
Regardless of whether they occur in the germline or
postzygotically, some de novo mutations lead to a single
Mendelian phenotype in which the mosaic and constitu-
tive form are part of the same clinical spectrum [159].
For example, pathogenic mutations in genes involved in
epileptic encephalopathies [160] and cerebral cortical
malformations [161] have been shown to cause similar
phenotypes when they arise either in the germline or as
postzygotic de novo mutations leading to mosaicism in
the brain. However, in some of these cases, mosaicism
might cause a clinical phenotype milder than a constitu-
tive mutation [162, 163].
De novo mutations can also result in different pheno-
types when they are present in the germline or arise
postzygotically [164]. Some de novo mutations lead to
developmental disorders only if the de novo mutation
occurs postzygotically, as the constitutive presence of
the mutation is suspected to be lethal [165, 166]. Exam-
ples of this include Proteus syndrome (caused by AKT1
mutations) [152], Sturge-Weber syndrome (GNAQ)
[153], and CLOVES syndrome (PIK3CA) [167]. A com-
mon feature to these disorders is that they are caused by
mutations known to lead to activation of cellular prolife-
ration pathways and overgrowth. The mutations with
the strongest effect generally result in more-severe de-
velopmental alterations [168], suggesting that the type of
de novo mutation influences the expression of the
phenotype. Remarkably, the mutations with the stron-
gest effect on activation have also been observed as som-
atic events in cancer [168], for which constitutive
activation of cellular proliferation pathways is a major
hallmark [169]. This finding supports the view that not
only the type of pathogenic mutation but also the time
at which the mutation occurs is crucial in defining its
consequences.
The timing of a postzygotic mutation determines the
percentage of affected cells in the organism and the type
of tissues involved [90, 153]. For instance, the same gen-
etic alteration in genes in the RAS–MAPK pathway can
result in very diverse phenotypes, depending on the tim-
ing at which they arise [164, 170, 171]. Mutations in
HRAS mutating codon G12 of the HRAS protein have
been identified in Costello syndrome when present in
the germline [172], but postzygotic and embryonic occur-
rences of mutations in this residue have been observed in
Schimmelpenning syndrome [164], sebaceous nevus [164],
keratinocytic epidermal nevi [173], and early-onset blad-
der cancer [157, 174]. Furthermore, identical mutations in
the phosphoinositide-3-kinase PIK3CA can cause different
phenotypes, ranging from different overgrowth syndromes
[154] to lymphatic [175] and venous malformations [176],
depending on the tissue distribution. Therefore, the timing
of a pathogenic de novo mutation is likely instrumental in
defining its phenotypic consequences as it determines
the burden placed by the mutation upon the organism,
including the type of tissues affected and the percentage
of cells in which the mutation is present [90, 153].
Finally, an important characteristic of postzygotic muta-
tions is that they generate genetically distinct populations
of cells that coevolve within a single organism. This can
lead to competition between populations of cells [177] or
generate interference in signal transduction between cells
[178, 179]. For example, craniofrontonasal syndrome is an
X-linked disorder in which women with germline muta-
tions and men with postzygotic mutations have a more
severe phenotype than men with germline mutations,
owing to interference in cell signaling between different
cell populations [179].
Postzygotic de novo mutations have been implicated
in early-onset cancer [155, 157] and could well repre-
sent an early mutational event in the development of
cancer in the general population [156]. Additionally,
the high degree of mosaicism observed in a normal
human brain has led to the suggestion that pathogenic
postzygotic and somatic mutations could be at the source
of psychiatric disorders [180, 181]. The role of mosaic de
novo mutations is not yet fully appreciated, and it is to be
expected that our understanding of this class of muta-
tions will increase rapidly in the coming years because of
further technological improvements as well as access to
DNA from other (affected) tissues or even cell-free DNA
(cfDNA) as a source of DNA from multiple tissues
[182–184].
De novo mutations in clinical practice
The recent recognition of the importance of de novo
mutations in human disease has many implications for
routine genetic testing and clinical practice. De novo
mutations are now established as the cause of disease in
a large fraction of patients with severe early-onset disor-
ders, ranging from rare congenital malformation syn-
dromes [185, 186] to more-common neurodevelopmental
disorders, such as severe forms of intellectual disability
[33], epilepsy [31], and autism [29]. Together, these disor-
ders represent a substantial proportion of all patients seen
at neuropediatric and clinical genetics departments around
the world.
Pinpointing the genetic cause of a disorder caused by a
de novo mutation in an individual can be challenging
from the clinical point of view because of pleiotropy as
well as genetic heterogeneity underlying a single pheno-
type. For instance, intellectual disability can be caused
by de novo point mutations, indels, or CNVs in any of
hundreds of genes [117]. This obstacle to providing a
clinical diagnosis strongly argues for a reliable and
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affordable genomics approach that can be used to detect
these de novo mutations in large groups of patients.
Exome and genome sequencing (which additionally
offers the possibility of accurate detection of structural
variation) of patient–parent trios is ideal for this and will
soon become the first-tier diagnostic approach for these
disorders. A key advantage of this trio-based sequencing
approach is that it helps prioritize candidates by de novo
occurrence, allowing clinical laboratories to focus on the
most likely candidate mutations for follow-up and in-
terpretation (Box 3) [187]. The interpretation of candi-
date de novo mutations can be guided by the use of
different scores, such as the “residual variation intolerance
score” (RVIS), based on the comparison of rare versus
common missense human variation per gene [188]. Alter-
natively, “selective constraint scores” can be used,
based on the observed versus expected rare functional
variation per gene within humans [126].
The identification of a de novo mutation as the cause
of disease in a patient has several implications for the
patient and his or her family. First, the detection of the
genetic defect underlying the phenotype establishes a
genetic diagnosis that can be used to provide a prognosis
based on data from other patients with similar mutations
[189] and information about current treatment options
[190] and, in the future, for the development and applica-
tion of personalized therapeutic interventions [191]. Fur-
thermore, the identification of a de novo mutation offers
the parents of the affected patient an explanation as to
why the disorder occurred and might help deal with feel-
ings of guilt [192, 193]. In terms of family planning, the
identification of a de novo mutation as the cause of
disease in a child can be positive news with regard to
recurrence risk, as it is much lower than for recessive or
dominant inherited disorders (slightly above 1% versus 25
and 50%, respectively) [11, 158]. However, the recurrence
risk is strongly dependent on the timing of the mutation
as parental mosaicism for the mutation increases the risk of
recurrence [158]. Approximately 4% of seemingly de novo
mutations originate from parental mosaicism detectable in
blood [11], and recent work suggests that transmission of
parental mosaicism could explain up to 10% of de novo
mutations in autism spectrum disorder [194]. This entails
that a fraction of de novo mutations have an estimated
recurrence risk above 5% [158]. Furthermore, close to 7%
of seemingly de novo mutations arise as postzygotic
events in the offspring [88, 89, 91]. Parents of an individ-
ual with a postzygotic mutation have a low risk for recur-
rence of the mutation in an additional child, estimated as
being the same as the population risk [90]. Targeted deep
sequencing of a disease-causing mutation can be per-
formed to test for its presence in parental blood and
detect mosaicism in the offspring. Although it is not yet
offered on a routine basis, this kind of testing can provide
a personalized and stratified estimate of the recurrence
risk based on the presence or absence of mosaicism in the
parents or in the offspring.
Finally, it is impossible to prevent de novo muta-
tions from arising in the germline of each new gener-
ation, but attention must be brought to the factors
that increase the number of de novo mutations in the
offspring. The single most important risk factor is ad-
vanced paternal age at conception [15], which is of
great importance from an epidemiological perspective
since most couples in Western countries are having
children at later ages. In fact, this increase in de novo
mutations with paternal age at conception might ex-
plain epidemiological studies that link increased paternal
age to increased risk of neurodevelopmental disorders in
offspring [195]. A recent population-genetic modeling
study, however, indicated that de novo mutations might
not explain much of the increased risk of psychiatric dis-
orders in children born to older fathers [122]. While this
might be the case for relatively mild and later-onset
phenotypes such as schizophrenia, de novo mutations are
responsible for the majority of the most severe pediatric
disorders arising in outbred populations [10, 196]. At
present, most attention, advice, and guidelines are focused
on advanced maternal age as a public health issue. It is
evident from current work on de novo mutations that
advising the public, including policy makers, on poten-
tial risks of advanced paternal age and the burden it might
bring on society is crucial. An extreme “solution” if
reproduction is to be postponed might be to promote
cryopreservation of oocytes and sperm [197], a measure
under much debate that has been termed “social freezing”.
Conclusions and future directions
Advances in sequencing technologies have provided us
with the ability to identify systematically most if not all
de novo mutations in a genome. This has boosted fun-
damental research into the evolution of our genome by
providing insight into the mechanisms that play a role in
mutagenesis, the origins of these mutations, and their
distribution throughout the genome. While most of this
research has been focused on germline mutations, we now
see a shift towards the detection and study of somatic de
novo mutations also for non-cancer phenotypes, greatly
facilitated by more accurate and deeper-coverage sequen-
cing technologies. Next-generation sequencing has also
boosted research and diagnostics on sporadic diseases.
The routine detection of de novo mutations by trio-based
sequencing of patients and their unaffected parents in
research as well as in diagnostics will soon allow the
identification of most disease-causing genes involved in
sporadic monogenic disorders. This will allow for the
classification of different developmental and neurodeve-
lopmental disorders based on the underlying genotype
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rather than solely on the phenotype. In turn, this offers
the possibility of targeted medical consultations and inter-
ventions, engagement in gene-specific patient groups,
and, in some cases, treatment. The study of de novo muta-
tions will shift more and more towards the detection and
characterization of non-coding de novo mutations in dis-
ease. Although a phenomenal challenge that will require
large-study cohorts and detailed functional validation, the
limited number of de novo mutations per genome reduces
the search space for pathogenic non-coding mutations, as
was shown recently for non-coding de novo CNVs [198].
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